Nachrichten zur Bristol-Myers Squibb Co. Aktie

BMY Reports Mixed Phase III Trial Results, Stock Down

Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced…

Bristol Myers Squibb: Phase-3-Daten zum Krebsmedikament validieren den Ausbau der Präzisionsonkologie

Der Konzern fokussiert sich auf Zukäufe, um Umsatzeinbußen durch auslaufende Patente auszugleichen. Der Wirkstoff RYZ101 erreichte in einer klinischen…

Bristol Myers falls 3% despite positive cancer drug trial results

Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an…

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?

Youll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and…

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?

Youll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and…

Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity

…

Bristol-Myers Squibb Aktie: Leerink zieht die Reißleine - gleich drei Hoffnungsträger sorgen für Zweifel

New YorkBoston, MA (www.aktiencheck.de) - Bristol Myers Squibb-Aktienanalyse von Leerink Partners:Leerink habe die Bristol-Myers-Squibb-Aktie von "outperform" auf "market perform" abgestuft…

Bristol-Myers Squibb: Patent Cliff Is Still A Problem

…

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly…

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Johnson & Johnsons revenue base runs roughly double Bristol-Myers Squibbs, with the gap showing signs of widening over the past…

3 Numbers That Explain Bristol Myers Squibbs Dirt Cheap Valuation

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and…

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at…

Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?

Bristol Myers Squibbs growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.…

Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?

As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.…

How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?

Collecting $10,000 a year from Bristol Myers Squibb sounds straightforward until you factor in a looming patent cliff that threatens…

Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors

Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to…

Bristol Myers Squibbs Breakout Is Here: Portfolio Renewal Gaining Momentum

…

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous…

Gov. Braun Announces $173 Million RayzeBio Investment, 100 New Jobs as Indianas Life Sciences Sector Grows

Bristol Myers Squibb expansion set to create high-wage jobs, advance radiopharmaceutical innovation in Indiana INDIANAPOLIS – Indiana Governor Mike Braun today…

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.…

COCP: $5 Million Private Placement with OPKO Health

By David Bautz, PhDNASDAQ: COCPREAD THE FULL COCP RESEARCH REPORTBusiness UpdateCDI-988 Approaches Key ReadoutCocrystal Pharma, Inc. (NASDAQ: COCP) is continuing…

AstraZeneca Vs. Bristol-Myers Squibb: Whos The Better Bargain For Investors?

…

BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibbs Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.…

Schrödinger outlines 10%-15% 2026 ACV growth as Bristol Myers Squibb deploys Bunsen

…

AstraZeneca-BMY megadeal talk sparks huge market rift

Two of the worlds biggest drugmakers moved in opposite directions on Monday, and the split says a lot about how…

AstraZeneca Investors See Little Logic in Bristol Tie-Up

AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400…

Bristol-Myers Squibb and AstraZeneca said to discuss megamerger

Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?…

Stocks making the biggest moves premarket: Alibaba, Bristol-Myers Squibb, eBay & more

These are the stocks posting the largest moves premarket.…

Analysts baffled by AstraZenecas interest in Bristol Myers Squibb

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled…

Analysts baffled by AstraZenecas interest in Bristol Myers Squibb

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled…

AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb

Shares in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) fell 7% to 11,723p on Monday after news that Britains biggest drugmaker is in talks…

AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb

Shares in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) fell 7% to 11,723p on Monday after news that Britains biggest drugmaker is in talks…

Morgan Stanley uncovers major Bristol Myers stock signals

Bristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report…

Pharma: Astra-Zeneca erwägt offenbar 400-Milliarden-Fusion mit US-Rivalen Bristol-Myers Squibb

Der Zusammenschluss wäre eine der größten Fusionen in der Wirtschaftsgeschichte. Ob es zu einem Deal kommt, ist jedoch noch offen.…

AstraZeneca shares slide 7% after reports of Bristol Myers talks

AstraZenecas shares fell sharply on Monday as analysts and investors questioned the logic of a possible tie-up with Bristol Myers…

FTSE 100 Live: Blue-chips to start August on front foot, AstraZeneca merger talks reported

7.47am: AstraZeneca in talks over $400 billion mega-merger AstraZeneca is in talks with Bristol Myers Squibb over a potential merger to…

JPMorgan belässt Astrazeneca auf Overweight - Ziel 16000 Pence

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca auf "Overweight" mit einem Kursziel von 16000…

Bristol Myers Squibb Isnt Nearly as Cheap as It Looks -- Heres the 1 Thing That Could Change That

Bristol Myers Squibbs P/E ratio is below the industry average, but you have to take this key fact into consideration…

Why Bristol Myers Squibb Stock Topped the Market on Thursday

It notched convincing beats on analyst estimates with its second-quarter performance.…

Bristol-Myers Squibb Company (BMY) Q2 2026 Earnings Call Transcript

…

Israel "Izzy" Englander Increased His Position in This Pharma Stock by 780%. Does He Know Something Wall Street Doesnt?

Analysts arent nearly as bullish about Bristol Myers Squibb as this billionaire hedge fund manager is.…

Bristol Myers Squibb – Der US-Pharmariese rüstet mit NVIDIAs neuestem KI-Supercomputer die Medikamentenforschung auf!

Bristol Myers Squibb kauft als erster Life-Sciences-Konzern einen Nvidia-Supercomputer der neuen Vera-Rubin-Generation für die KI-gestützte Medikamentenforschung. Der Konzern verkürzt die…

Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today

Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.99% change compared to…

Is Bristol Myers Squibbs 4.3% Dividend Yield Safe? Heres What Investors Need to Know.

This big pharma stock looks attractive for income investors -- but it comes with some risk.…

House committee investigates Merck, AbbVie over China trials

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China…

Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How…

Heres Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.…

ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community

By M. MarinNASDAQ: ORMPREAD THE FULL ORMP RESEARCH REPORTORMP shares to be added to the Russell 2000® & Russell 3000®As…

How Safe is Bristol Myers Squibbs Dividend? Heres My Honest Take.

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.…